KDR and Cowden syndrome 1: Similarly, regorafenib, a VEGF receptor targeting drug, was able to prolong progression-free survival of advanced CS patients [96] suggesting a possible role for pazopanib and other VEGFR-targeting drugs in the therapy of CS.